A multimodal strategy combining targeted trastuzumab deruxtecan, localized radiotherapy, and surgical decompression achieved near-complete radiological resolution and substantial neurological recovery ...
A retrospective case series links a tissue factor-targeted antibody-drug conjugate to severe ocular surface toxicity in five of 116 trial ...
A scientific review highlights clinical and preclinical evidence supporting patritumab deruxtecan as an emerging HER3-targeted therapy across diverse breast cancer ...
Cytoplasmic B7-H3 staining clearly separates salivary gland carcinomas from normal salivary tissue, while membranous staining shows weaker signals and no ...
A first-in-human Phase 1/2a trial of the B7-H4-targeting antibody-drug conjugate puxitatug samrotecan reported partial responses in heavily pretreated ovarian, endometrial ...
A retrospective Indian analysis of 101 patients reports real-world efficacy and safety outcomes for the trastuzumab emtansine biosimilar UJVIRA in ...
A post-hoc safety analysis of the phase 3 OptiTROP-Breast01 trial found that sacituzumab tirumotecan's key adverse events arose mainly in ...
A Taiwanese case report documents 21-month survival after leptomeningeal metastasis in a rare triple-negative breast cancer subtype treated with sacituzumab ...
In mice, an antibody targeting CADM1 in the olfactory epithelium delivered significantly higher brain levels of the drug MMAE than ...
A retrospective study of 1,919 breast cancer patients in China found core needle biopsy reliably determines binary HER2 status but ...
A single case report describes a 73-year-old man with HER2-low metastatic urothelial carcinoma whose liver metastases nearly resolved after treatment ...
A retrospective international analysis found male metastatic urothelial carcinoma patients survived longer on enfortumab vedotin than females, with higher NECTIN-4 ...
A single-patient case report documents delayed toxic epidermal necrolysis after six cycles of pembrolizumab and enfortumab vedotin for metastatic urothelial ...
The phase III TAISHAN-302 trial found that the anti-B7-H3 antibody-drug conjugate Tam-Peli reduced the risk of death by 54 percent ...
Kansai Medical University Hospital gave the first worldwide dose of investigational CD25-directed antibody drug conjugate DS1025 in a global Phase ...
A CD276-targeted antibody-drug conjugate combined with mitochondrial-disrupting gene therapy outperformed either treatment alone in two preclinical models of metastatic triple-negative ...
Brentuximab vedotin has transformed the outlook for patients with CD30-positive lymphomas, but the antibody-drug conjugate carries a neurological price that ...
A new review argues that B7-H3 positivity measured by immunohistochemistry is necessary but not sufficient to predict response to antibody-drug ...
A rare but serious infusion accident has been documented for the first time in the medical literature. Urologists at University ...
New research links the secreted glycoprotein LGALS3BP to selective enrichment of microRNAs and the RNA-binding protein SRSF1 in neuroblastoma extracellular ...
